Despite several studies strongly support the inhibitory and prognostic value of BTLA and HVEM in hematological cancers, there is scarce information to date about the antitumor effects associated to disruption of BTLA/HVEM axis. The gene discussed is BTLA; the disease is hematopoietic and lymphoid cell neoplasm.